BriaCell’s Phase 3 Patient Enrollment on Track for 1H2026 Topline Data Readout

Core Insights - BriaCell Therapeutics Corp. is advancing its Phase 3 clinical study for Bria-IMT, having screened over 230 patients and enrolled over 160, with topline data expected in the first half of 2026 [1][9] Group 1: Clinical Study Progress - The Phase 3 study is evaluating Bria-IMT in combination with an immune checkpoint inhibitor against physician's choice therapy in patients with metastatic breast cancer [2][4] - An interim analysis will be conducted once 144 patient events (deaths) occur, focusing on overall survival as the primary endpoint [5][9] - The enrollment pace has exceeded expectations, indicating strong engagement from clinical sites and interest from patients [3][9] Group 2: Regulatory Status - The Bria-IMT combination regimen has received FDA Fast Track designation, which may facilitate its approval process [5][9] - Positive results from the study could lead to full approval and marketing authorization for Bria-IMT in metastatic breast cancer patients [2][5] Group 3: Company Overview - BriaCell is a clinical-stage biotechnology company focused on developing novel immunotherapies aimed at transforming cancer care [7]